Acute Respiratory

A new report finds that a new COVID-19 variant — BA.2.86, or Pirola — may not be as contagious than originally thought. That’s good news for long-term care communities, who have been told to brace...

CDC director Rochelle Walensky has greenlit the use of two new respiratory syncytial virus (RSV) vaccines for preventing severe disease in older adults, emphasizing their use in vulnerable groups such...

A panel of experts decided that people aged 60 years and older may receive either of two recently approved vaccines for preventing respiratory syncytial virus infections. But the recommendation is not...

Pfizer’s Abrysvo was found to be 67% effective in preventing confirmed RSV in cases with two symptoms, and even more effective in preventing disease with three or more symptoms, clinical trial data...

Arexvy has shown 82.6% efficacy against the development of lower respiratory tract disease caused by the virus, developer GSK reports.

With FDA approval expected in May, both Pfizer and GSK say they are set for a 2023 launch of their respiratory syncytial virus vaccines for older adults.

In landmark decisions, the advisers recommended that two new vaccines for respiratory syncytial virus (RSV) should be approved for use in older adults. 

With two difficult seasons behind them, nursing homes have an opportunity to have “a very different winter,” said White House COVID lead Ashish Jha, MD, at an AHCA/NCAL webinar.

The hospitalization rate for seniors with respiratory syncytial virus, also known as RSV, is 10 times higher than usual for the season, federal data show.

Five medical societies have created a toolkit designed to help clinicians increase the effectiveness, accessibility and awareness of oral antiviral therapeutics and COVID-19 booster vaccines.